PCL Inc is a Korea-based company principally engaged in development and manufacture of vitro diagnostic medical device for immunological diagnosis. The Companyâ€™s products include blood bank screening products and quick diagnostic products. And the Company also provides platform services.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 2025-03-21			5-day change	1st Jan Change
6,040.00 ^KRW	-1.63%		-.--%	-

24-12-29	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
24-08-29	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI

Market Cap	16.8B 11.31M 9.9M 9.14M 8.42M 15.85M 1.09B 16.22M 109M 42.87M 533M 42.45M 41.52M 1.84B	P/E 2023	-7.17x	P/E 2024	-0.59x
Enterprise Value	23.83B 16.04M 14.04M 12.97M 11.94M 22.48M 1.54B 23M 155M 60.8M 756M 60.2M 58.89M 2.61B	EV / Sales 2023	22.8x	EV / Sales 2024	31.9x
Free-Float	98.99%	Yield 2023 *	-	Yield 2024	-

24-12-29	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
24-08-29	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI
24-08-21	PCL, Inc. announced that it expects to receive KRW 4.004999835 billion in funding	CI
24-06-24	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
24-06-20	Tiger Company Ltd. announced that it has received KRW 8.3 billion in funding from PCL, Inc.	CI
24-01-15	PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets	CI
23-12-25	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets	CI
23-12-20	PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets	CI
23-12-14	PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
23-05-31	South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13%	MT
23-05-31	PCL to Raise 36 Billion Won via Share Issuance	MT
23-03-22	PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
22-12-28	PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	CI

3 years	5,900	94,500
5 years	5,900	380,000
10 years	5,900	523,333.33

PCL, Inc. Stock

Stocks

A241820

KR7241820000

Biotechnology & Medical Research

Valuation: PCL, Inc.

Latest news : PCL, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: PCL, Inc.

Bio Diagnostics & Testing

Financials

Company Profile

Income Statement and Estimates

Manager	Title	Age	Since
So-Yeon Kim CEO	Chief Executive Officer	55	-
Seong-Woo Lee SAM	Sales & Marketing	42	2024-03-27
Mu-Yong So AUD	Comptroller/Controller/Auditor	53	2024-03-27

Director	Title	Age	Since
So-Yeon Kim BRD	Director/Board Member	55	-
Chul-Joon Kim BRD	Director/Board Member	73	-
Mu-Yong So BRD	Director/Board Member	53	2024-03-27

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCL, INC.	-1.63%	-.--%	-.--%	-83.71%	11.3M
VERACYTE, INC.	-0.15%	+3.79%	+151.51%	+98.56%	4.72B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+3.71%	+8.83%	+120.60%	+201.98%	3.67B
IOVANCE BIOTHERAPEUTICS, INC.	+7.30%	+18.20%	+124.22%	-38.65%	2.23B
CAREDX, INC.	-1.51%	+39.35%	+233.45%	+285.35%	2.05B
BGI GENOMICS CO., LTD.	-5.50%	-0.75%	-29.67%	-37.76%	2.04B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+2.12%	+18.88%	+197.94%	-41.99%	1.07B
SEEGENE, INC.	-2.39%	-1.55%	-10.78%	+35.95%	875M
HANGZHOU ALLTEST BIOTECH CO., LTD.	-4.16%	+6.17%	-34.21%	-11.74%	513M
CURIOX BIOSYSTEMS CO., LTD	-3.06%	-3.18%	-3.97%	-	476M
Average	-0.53%	+8.77%	+74.91%	+45.33%	1.76B
Weighted average by Cap.	+0.65%	+10.75%	+115.35%	+93.64%

	2023	2024
Net sales	8.43B 5.67M 4.96M 4.59M 4.22M 7.95M 546M 8.13M 54.72M 21.5M 267M 21.29M 20.83M 923M	1.25B 839K 734K 678K 624K 1.18M 80.7M 1.2M 8.09M 3.18M 39.52M 3.15M 3.08M 136M
Net income	-20.32B -13.67M -11.97M -11.05M -10.18M -19.16M -1.32B -19.61M -132M -51.83M -644M -51.32M -50.21M -2.23B	-52.34B -35.22M -30.83M -28.47M -26.22M -49.36M -3.39B -50.51M -340M -134M -1.66B -132M -129M -5.73B
Net Debt	7.2B 4.85M 4.24M 3.92M 3.61M 6.79M 467M 6.95M 46.76M 18.38M 228M 18.2M 17.8M 789M	7.03B 4.73M 4.14M 3.82M 3.52M 6.63M 455M 6.78M 45.63M 17.93M 223M 17.76M 17.37M 770M